The biopharmaceutical industry’s unique role in responding to COVID-19
By Richard Moscicki, M.D. | April 2, 2020
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock...
Read More
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
By Gabby Migliara | April 1, 2020
Recently, PhRMA hosted a teleconference to provide an update on our member companies’ around-the-clock efforts in developing treatments and vaccines for COVID-19, a disease caused by a novel...
Read More
COVID-19 Response: Supporting the frontline
By Stephen J. Ubl | March 30, 2020
Updated 4/4/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...
Read More
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
By Guest Contributor | March 26, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
America’s biopharmaceutical companies are working around the clock to beat coronavirus
By Holly Campbell | March 20, 2020
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment to finding solutions to prevent,...
Read More
Guest post: Takeda’s efforts to address COVID-19
By Guest Contributor | March 19, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest ...
Read More
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
By Andrew Powaleny | March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...
Read More
Nearly 400 cell and gene therapies in development to target a broad range of diseases
By Andrew Powaleny | March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...
Read More
Rare Disease Day 2020: Progress toward cures
By Richard Moscicki, M.D. | February 24, 2020
Today kicks off Rare Disease Week, an annual opportunity to celebrate the incredible progress that has been made to treat rare diseases and reflect on the need for continued research and...
Read More
IP Explained: Four key takeaways from new Bayh-Dole white paper
By Tom Wilbur | February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
